AVANIR Pharmaceuticals Presents Data on Novel Allergy/Asthma Compound at AAAAI National Meeting
No orally active allergy drugs are currently marketed for the treatment of excess IgE or Th2 cytokines, and AVANIR believes that a compound that acts on these critical mediators would provide a valuable new tool for the treatment of asthma and allergic rhinitis. An Investigational New Drug (IND) application is pending with the U.S. Food and Drug Administration (FDA).
About AVP 13358
AVP 13358 is a novel drug molecule discovered by scientists at AVANIR that is intended to inhibit the production of IgE antibodies, a well-known mediator of allergy and asthma. In addition to its effect on IgE, this compound has demonstrated an ability to suppress the antigen-stimulated IL-4 and IL-5 responses with potencies similar to those observed for IgE suppression. AVP 13358 also suppresses markers of disease in mouse models of asthma, including pulmonary lavage levels of IL-4, IL-5, eosinophils, and lymphocytes, as well as expression of CD23 and the IL-4 receptor (IL-4Ralpha) on leukocytes. No inhibitory effects on antigen-specific IgG responses were observed. AVP 13358 is orally active and appears to be selective for the suppression of Th2 cytokine-mediated diseases. The abstract accepted for presentation at the 60th Anniversary AAAAI meeting was published in the February 2003 supplement of the Journal of Allergy and Clinical Immunology.
About the Company
AVANIR Pharmaceuticals, based in San Diego, is a drug discovery and development company with a commercialized FDA-approved product (Abreva(R)) and a product in Phase III clinical trials (Neurodex(TM)). AVANIR is engaged in small molecule research to develop treatments for central nervous system disorders and inflammatory diseases. Through the use of its Xenerex(TM) technology, AVANIR also develops human monoclonal antibodies for therapeutic applications. Further information about AVANIR can be found at www.avanir.com .
The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the Company's most recent Annual Report on Form 10-K and other publicly available information regarding the Company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". Our IgE modulation program competes with other research approaches and compounds under development by large pharmaceutical and biotechnology companies. Preclinical research findings are not always supportable by evidence obtained from subsequent clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the Company.
For further information please contact: Analyst/Investor, Tricia Ross of FRB|Weber Shandwick, +1-310-407-6540, email@example.com , for AVANIR Pharmaceuticals; or Media, Dennis Ellman of Beck Ellman Heald, +1-858-453-9600, firstname.lastname@example.org , for AVANIR Pharmaceuticals; or Investor Relations, Patrice Saxon of AVANIR Pharmaceuticals, +1-858-622-5202, email@example.com .
SOURCE AVANIR Pharmaceuticals
Analyst/Investor, Tricia Ross of FRB|Weber Shandwick, +1-310-407-6540, firstname.lastname@example.org , for AVANIR Pharmaceuticals; or Media, Dennis Ellman of Beck Ellman Heald, +1-858-453-9600, email@example.com , for AVANIR Pharmaceuticals; or Investor Relations, Patrice Saxon of AVANIR Pharmaceuticals, +1-858-622-5202, firstname.lastname@example.org
Copyright (C) 2003 PR Newswire. All rights reserved.